Salivary Concentrations of Chemerin, α-Defensin 1, and TNF-α As Potential Biomarkers in the Early Diagnosis of Colorectal Cancer

Overview

Journal Metabolites

Publisher MDPI

Date 2022 Aug 25

PMID 36005576

Authors

Dariusz Waniczek

Elzbieta Swietochowska

Miroslaw Snietura

Pawel Kiczmer

Zbigniew Lorenc

Malgorzata Muc-Wierzgon

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is one of the most prevalent cancers worldwide. There is a great interest and need to find simple, inexpensive, and minimally invasive diagnostic tests. The aim of the study was to analyze the salivary concentrations of chemerin, α-defensin 1, and TNF-α in colorectal cancer (CRC) patients and in a healthy control group. The concentration of these proteins was simultaneously determined in the serum of subjects. We also aimed to assess the correlation of these results and selected clinicopathological features. This prospective study was comprised of 39 CRC patients and 40 control group patients. Salivary and serum concentrations were determined by enzyme immunoassays. The salivary and serum concentrations of chemerin, α-defensin 1, and TNF-α were significantly higher in cancer patients compared to the control group. No correlation was found between concentrations of the proteins and the clinical stage of cancer and tumor location. The ROC curve analysis showed that although salivary concentrations of all proteins showed 100% sensitivity and 100% specificity, serum concentrations of the analyzed proteins were characterized by 100% sensitivity and over 90% specificity. The assessment of chemerin, α-defensin 1, and TNF-α concentrations in saliva seem to have great potential as quick and useful biomarkers in the early diagnosis of CRC.

Citing Articles

Natural Antimicrobial Peptides and Their Synthetic Analogues for Effective Oral Microflora Control and Oral Infection Treatment-The Role of Ceragenins in the Development of New Therapeutic Methods.

Czarnowski M, Wnorowska U, Luckiewicz M, Dargiewicz E, Spalek J, Okla S Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770567 PMC: 11678171. DOI: 10.3390/ph17121725.

New gold(III) complexes TGS 121, 404, and 702 show anti-tumor activity in colitis-induced colorectal cancer: an in vitro and in vivo study.

Wlodarczyk J, Krajewska J, Talar M, Szeleszczuk L, Gurba A, Lipiec S Pharmacol Rep. 2023; 76(1):127-139.

PMID: 38082190 PMC: 10830623. DOI: 10.1007/s43440-023-00558-1.

Induction of Endogenous Antimicrobial Peptides to Prevent or Treat Oral Infection and Inflammation.

Morio K, Sternowski R, Brogden K Antibiotics (Basel). 2023; 12(2).

PMID: 36830272 PMC: 9952314. DOI: 10.3390/antibiotics12020361.

References

Fellermann K, Stange D, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins C . A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet. 2006; 79(3):439-48. PMC: 1559531. DOI: 10.1086/505915. View

Negroni A, Stronati L, Pierdomenico M, Tirindelli D, Di Nardo G, Mancini V . Activation of NOD2-mediated intestinal pathway in a pediatric population with Crohn's disease. Inflamm Bowel Dis. 2009; 15(8):1145-54. DOI: 10.1002/ibd.20907. View

Tzanavari T, Giannogonas P, Karalis K . TNF-alpha and obesity. Curr Dir Autoimmun. 2010; 11:145-56. DOI: 10.1159/000289203. View

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

Weigert J, Obermeier F, Neumeier M, Wanninger J, Filarsky M, Bauer S . Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Inflamm Bowel Dis. 2009; 16(4):630-7. DOI: 10.1002/ibd.21091. View

Zidi I, Mestiri S, Bartegi A, Ben Amor N . TNF-alpha and its inhibitors in cancer. Med Oncol. 2009; 27(2):185-98. DOI: 10.1007/s12032-009-9190-3. View

Hussain S, Harris C . Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007; 121(11):2373-80. DOI: 10.1002/ijc.23173. View

Erdogan S, Yilmaz F, Yazici O, Yozgat A, Sezer S, Ozdemir N . Inflammation and chemerin in colorectal cancer. Tumour Biol. 2015; 37(5):6337-42. DOI: 10.1007/s13277-015-4483-y. View

Kiczmer P, Senkowska A, Kula A, Dawidowicz M, Strzelczyk J, Zajdel E . Assessment of CMKLR1 level in colorectal cancer and its correlation with angiogenic markers. Exp Mol Pathol. 2020; 113:104377. DOI: 10.1016/j.yexmp.2020.104377. View

10.

Sethi G, Sung B, Aggarwal B . TNF: a master switch for inflammation to cancer. Front Biosci. 2008; 13:5094-107. DOI: 10.2741/3066. View

11.

Yagi M, Sasaki Y, Abe Y, Yaoita T, Sakuta K, Mizumoto N . Association between High Levels of Circulating Chemerin and Colorectal Adenoma in Men. Digestion. 2019; 101(5):571-578. DOI: 10.1159/000501477. View

12.

Liu J, Duan Y . Saliva: a potential media for disease diagnostics and monitoring. Oral Oncol. 2012; 48(7):569-77. DOI: 10.1016/j.oraloncology.2012.01.021. View

13.

Wang N, Wang Q, Feng Y, Shang W, Cai M . Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue. Clin Oral Investig. 2013; 18(3):997-1004. DOI: 10.1007/s00784-013-1046-8. View

14.

Jin G, Kawsar H, Hirsch S, Zeng C, Jia X, Feng Z . An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. PLoS One. 2010; 5(6):e10993. PMC: 2882331. DOI: 10.1371/journal.pone.0010993. View

15.

Chamberland J, Berman R, Aronis K, Mantzoros C . Chemerin is expressed mainly in pancreas and liver, is regulated by energy deprivation, and lacks day/night variation in humans. Eur J Endocrinol. 2013; 169(4):453-62. PMC: 3798003. DOI: 10.1530/EJE-13-0098. View

16.

Alkady M, Abdel-Messeih P, Nosseir N . Assessment of Serum Levels of the Adipocytokine Chemerin in Colorectal Cancer Patients. J Med Biochem. 2019; 37(3):313-319. PMC: 6298460. DOI: 10.1515/jomb-2017-0062. View

17.

Guadagni F, Ferroni P, Palmirotta R, Portarena I, Formica V, Roselli M . Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy. In Vivo. 2007; 21(2):147-61. View

18.

Mizukawa N, Sugiyama K, Fukunaga J, Ueno T, Mishima K, Takagi S . Defensin-1, a peptide detected in the saliva of oral squamous cell carcinoma patients. Anticancer Res. 1999; 18(6B):4645-9. View

19.

Lin W, Karin M . A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117(5):1175-83. PMC: 1857251. DOI: 10.1172/JCI31537. View

20.

Wang C, Wu W, Liu X, To K, Chen G, Yu J . Increased serum chemerin level promotes cellular invasiveness in gastric cancer: a clinical and experimental study. Peptides. 2013; 51:131-8. DOI: 10.1016/j.peptides.2013.10.009. View